Effectiveness of EGFR‐TKI rechallenge immediately after PD‐1 blockade failure

Effectiveness of EGFR‐TKI rechallenge immediately after PD‐1 blockade failure

Abstract Background There is currently insufficient information available on effective therapies that can be administered to patients with non‐small cell cancer (NSCLC) who develop resistance to epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs). However, sequential treatment vi...

Full description

Bibliographic Details
Main Authors:	Kyoichi Kaira, Kunihiko Kobayashi, Ayako Shiono, Ou Yamaguchi, Kosuke Hashimoto, Atsuto Mouri, Shun Shinomiya, Yu Miura, Hisao Imai, Hiroshi Kagamu
Format:	Article
Language:	English
Published:	Wiley 2021-03-01
Series:	Thoracic Cancer
Subjects:	EGFR‐TKI immune checkpoint inhibitor lung cancer PD‐1 rechallenge
Online Access:	https://doi.org/10.1111/1759-7714.13864

Similar Items

Different incidence of interstitial lung disease according to different kinds of EGFR‐tyrosine kinase inhibitors administered immediately before and/or after anti‐PD‐1 antibodies in lung cancer
by: Takahiro Uchida, et al.
Published: (2019-04-01)

Effectiveness and Safety of EGFR-TKI Rechallenge Treatment in Elderly Patients with Advanced Non-Small-Cell Lung Cancer Harboring Drug-Sensitive EGFR Mutations
by: Yutaka Yamada, et al.
Published: (2021-09-01)

Biomarker-Guided Anti-Egfr Rechallenge Therapy in Metastatic Colorectal Cancer
by: Davide Ciardiello, et al.
Published: (2021-04-01)

PEGylated Liposomal Doxorubicin Rechallenge following Doxorubicin-induced Pancreatitis
by: Luke Ardolino, et al.
Published: (2020-12-01)

Rechallenge of voriconazole successfully tolerated after hepatic toxicity
by: O. Narumoto, et al.
Published: (2020-01-01)

Effect of Systemic Steroid Use for Immune-Related Adverse Events in Patients with Non-Small Cell Lung Cancer Receiving PD-1 Blockade Drugs
by: Atsuto Mouri, et al.
Published: (2021-08-01)

Efficacy and Feasibility of Programmed Death-1/Programmed Death Ligand-1 Blockade Therapy in Non-Small Cell Lung Cancer Patients With High Antinuclear Antibody Titers
by: Atsuto Mouri, et al.
Published: (2021-03-01)

Ofloxacin-ornidazole fixed-dose combination medication-induced pancreatitis with positive rechallenge
by: Nikhil Bush, et al.
Published: (2020-01-01)

Glasgow prognostic score predicts efficacy and prognosis in patients with advanced non‐small cell lung cancer receiving EGFR‐TKI treatment
by: Norimitsu Kasahara, et al.
Published: (2020-08-01)

Successful rechallenge with cetuximab after progression with nivolumab for recurrent cervical lymph node metastasis from carcinoma of the tongue
by: Yasuyuki Asada, et al.
Published: (2021-07-01)

Cetuximab Rechallenge and Monotherapy in Patients with Squamous Cell Carcinoma of the Head and Neck
by: Greg Knutzen, et al.
Published: (2015-11-01)

Hyponatremia after initiation and rechallenge with trimethoprim–sulfamethoxazole in an older adult
by: Huntsberry AM, et al.
Published: (2015-07-01)

Successful afatinib rechallenge in a patient with non‐small cell lung cancer harboring EGFR G719C and S768I mutations
by: Tomomi Masuda, et al.
Published: (2020-08-01)

Effect of EGFR-TKI on Lymphangiogenesis of Lung Cancer with EGFR Mutation
by: Minghui CAI, et al.
Published: (2014-12-01)

EGFR-TKI plus bevacizumab versus EGFR-TKI monotherapy for patients with EGFR mutation-positive advanced non-small cell lung cancer-A propensity score matching analysis
by: Jeng-Shiuan Tsai, et al.
Published: (2021-09-01)

Safety and efficacy of cyclin-dependent kinase inhibitor rechallenge following ribociclib-induced limiting hypertransaminasemia
by: Jesús Fuentes-Antrás, et al.
Published: (2020-12-01)

Therapeutic effect of whole brain radiotherapy on advanced NSCLC between EGFR TKI-naïve and TKI-resistant
by: Lihao Zhao, et al.
Published: (2019-12-01)

Legal Protection of Indonesian Migrant Workers (TKI) Overseas (Case Study of BP3TKI North Sumatera Province)
by: Vinna Dinda Kemala, et al.
Published: (2020-01-01)

Immune-Related Adverse Events (irAE) in Cancer Immune Checkpoint Inhibitors (ICI) and Survival Outcomes Correlation: To Rechallenge or Not?
by: Heidar J. Albandar, et al.
Published: (2021-02-01)

EGFR-TKI ADR Management Chinese Expert Consensus
by: Chinese Society of Lung Cancer, Chinese Anti-Cancer Association
Published: (2019-02-01)

Retrospective Efficacy Analysis of Immune Checkpoint Inhibitor Rechallenge in Patients with Non-Small Cell Lung Cancer
by: Yuki Katayama, et al.
Published: (2019-12-01)

Pre‐existing interstitial lung disease does not affect prognosis in non‐small cell lung cancer patients with PD‐L1 expression ≥50% on first‐line pembrolizumab
by: Ou Yamaguchi, et al.
Published: (2021-02-01)

COMPARISON OF CHEMOTHERAPY RESPONSE AND ADVERSE EFFECTS OF DOUBLE-PLATINUM PLUS EGFR-TKI VERSUS DOUBLE-PLATINUM ALONE ON NSLCLC PATIENTS WITH DISEASE PROGRESSION AND EGFR-TKI TREATMENT
by: Laksmi Wulandari, et al.
Published: (2017-12-01)

Molecular Mechanism and Progression of Primary Resistance to EGFR-TKI - Analysis of 2 Cases
by: Meirong LIU, et al.
Published: (2019-01-01)

A Large Real-World Study on the Effectiveness of the Combined Inhibition of EGFR and MET in EGFR-Mutant Non-Small-Cell Lung Cancer After Development of EGFR-TKI Resistance
by: Li Liu, et al.
Published: (2021-10-01)

Clinical Developments for the EGFR-TKI Combined with Radiotherapy in Advanced Non-small Cell Lung Cancer
by: Xianan LI, et al.
Published: (2014-04-01)

EGFR‐mutated stage IV non‐small cell lung cancer: What is the role of radiotherapy combined with TKI?
by: Bailong Liu, et al.
Published: (2021-09-01)

Rechallenge with Lenvatinib after Refractoriness to Initial Lenvatinib Followed by Sorafenib in a Patient with Metastatic Papillary Thyroid Carcinoma
by: Masaki Takinami, et al.
Published: (2020-05-01)

The prognostic impact of neutrophil to lymphocyte ratio in advanced non-small-cell lung cancer patients treated with EGFR TKI
by: Phan TT, et al.
Published: (2018-11-01)

First-Generation EGFR-TKI Plus Chemotherapy Versus EGFR-TKI Alone as First-Line Treatment in Advanced NSCLC With EGFR Activating Mutation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Qiang Wu, et al.
Published: (2021-04-01)

Rechallenge with Multi-Targeted Tyrosine Kinase Inhibitors in Patients with Advanced Soft Tissue Sarcoma: A Single-Center Experience
by: Liu J, et al.
Published: (2021-03-01)

Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
by: Silvia La Monica, et al.
Published: (2017-12-01)

Alectinib-Induced Erythema Multiforme and Successful Rechallenge with Alectinib in a Patient with Anaplastic Lymphoma Kinase-Rearranged Lung Cancer
by: Tatsuo Kimura, et al.
Published: (2016-12-01)

Drastic antitumor response following administration of afatinib immediately after atezolizumab in a patient with epidermal growth factor receptor tyrosine kinase inhibitor‐resistant lung cancer
by: Toshiyuki Sumi, et al.
Published: (2021-07-01)

Clinical impact of post‐progression survival on overall survival in patients receiving nivolumab monotherapy as a second‐line treatment for advanced non‐small cell lung cancer
by: Hisao Imai, et al.
Published: (2021-04-01)

Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma
by: Da Hyun Kang, et al.
Published: (2020-06-01)

Severe hepatotoxicity due to osimertinib after nivolumab therapy in patients with non‐small cell lung cancer harboring EGFR mutation
by: Ou Yamaguchi, et al.
Published: (2020-04-01)

Rechallenge with First-Line Platinum Chemotherapy for Sensitive-Relapsed Small-Cell Lung Cancer
by: Toshihiro Shiozawa, et al.
Published: (2018-09-01)

REMARRY and PURSUIT trials: liquid biopsy-guided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancer
by: Hiromichi Nakajima, et al.
Published: (2021-06-01)

Abnormally activated OPN/integrin αVβ3/FAK signalling is responsible for EGFR-TKI resistance in EGFR mutant non-small-cell lung cancer
by: Yulong Fu, et al.
Published: (2020-12-01)